Milford, Massachusetts, U.S., September 14, 2026
Waters Corporation has announced the global commercial launch of the BD FACSDiscover™ A7 Cell Analyzer, a new spectral flow cytometry platform designed to improve experimental standardization, data consistency, and accessibility for researchers working in life sciences. The system combines advanced spectral resolution and sensitivity with automated quality-control capabilities, guided software workflows, and an integrated autoloader. According to Waters, the instrument is intended to support researchers in academia, pharmaceutical laboratories, and contract research organizations (CROs), with applications ranging from immunology research and biomarker discovery to drug development.
Advanced Spectral Technology Expands Cell Analysis
The BD FACSDiscover A7 Cell Analyzer incorporates BD SpectralFX™ Technology, previously available in the flagship BD FACSDiscover A8 Cell Analyzer. The technology enables researchers to examine more than 50 characteristics of an individual cell, providing a broad analytical palette for complex biological investigations. The platform is designed to support high-parameter experiments while maintaining sensitivity and consistency across measurements. This capability can be particularly relevant to immunology, cellular research, biomarker discovery, and drug development, where researchers increasingly rely on detailed characterization of cell populations. Waters said the system extends advanced spectral flow cytometry capabilities to a broader range of laboratories by combining performance with a focus on usability and standardization.
Automated Standardization Targets Reproducible Results
A central feature of the new analyzer is FACSTruQ™ Technology, which provides automated instrument calibration, setup, and quality control. Waters said this approach is designed to reduce differences associated with individual instruments, users, and laboratory sites, helping researchers generate more consistent results. According to company data, the analyzer achieved a coefficient of variation below 10% across more than 50 dyes, supporting the company’s focus on reproducibility in high-parameter flow cytometry. The platform also integrates BD FACSChorus™ Software, which provides guided workflows intended to help both experienced and newer users perform experiments more efficiently. Together with the integrated autoloader, these features are designed to streamline laboratory workflows and shorten the time between sample analysis and scientific insight.
Advertisement
Supporting Pharmaceutical and Biomedical Research
The commercial launch comes as laboratories increasingly require reproducible, high-dimensional cellular data for research and therapeutic development. Flow cytometry is widely used to characterize immune cells, investigate disease biology, identify biomarkers, and evaluate cellular responses during drug development. By combining spectral flow cytometry, automated quality control, software-guided workflows, and standardized instrument performance, the BD FACSDiscover A7 is positioned to address these research requirements. Waters also highlighted the platform’s potential applications in studies involving immune system disorders, cancer research, and treatment development. The company said the new analyzer builds on advances in high-color flow cytometry and expands access to technologies capable of supporting increasingly complex cellular experiments.
The BD FACSDiscover A7 Cell Analyzer is now commercially available globally through local representatives. Its launch represents an expansion of Waters’ flow cytometry portfolio and reflects the growing importance of standardization and reproducibility in advanced cell analysis. For pharmaceutical companies, biotechnology researchers, academic institutions, and CRO laboratories, technologies that can generate consistent high-parameter datasets may support more reliable research workflows and facilitate the interpretation of complex biological systems.
Source: Waters Corporation press release
